The Effects of Empagliflozin on Arterial Wall Characteristics
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT03639545
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 120 participants
- Registry
-
NCT03639545
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Slovenia
- Registry status
- Unknown status
Technical summary
Registry record NCT03639545. Randomized; triple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2018-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Empagliflozin on Arterial Wall Characteristics
- Condition
- Vascular Stiffness
- Condition
- Hypoglycemic Agents
- Condition
- Diabetes Complications
- Condition
- Diabetes Mellitus, Type 1
- Intervention (Drug)
- Empagliflozin 25mg
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Empagliflozin/Metformin
- Intervention (Drug)
- Placebos
- Lead sponsor
- University Medical Centre Ljubljana
Record details
- Record id
cardio:ct-nct03639545- Content hash
9d018ac96bde0d2b1bb1a2c5c6dcfe2b6e33714f508622bd3bddb1415197376a